SLCO1B1、ABCG2与SLCO2B1基因变异影响瑞舒伐他汀药代动力学
该研究通过全基因组关联分析及候选基因分析,在159例前瞻性研究参与者和88例已发表研究队列中探讨遗传变异对单剂量瑞舒伐他汀药代动力学的影响。结果提示SLCO1B1 c.521T>C与ABCG2 c.421C>A分别与瑞舒伐他汀AUC升高相关,SLCO1B1 c.388A>G和SLCO2B1 c.1457C>T与AUC降低相关;OATP1B1功能减弱或ABCG2功能缺失基因型者瑞舒伐他汀暴露增加,建议携带者降低剂量。
要点
- SLCO1B1 c.521T>C与瑞舒伐他汀AUC和峰浓度显著升高相关
- OATP1B1功能减弱表型者瑞舒伐他汀AUC增加2.1倍
- ABCG2 c.421A/A基因型者瑞舒伐他汀AUC增加2.2倍
核心结论
- SLCO1B1、ABCG2和SLCO2B1基因变异与瑞舒伐他汀药代动力学相关。
- SLCO1B1或ABCG2功能减弱基因型可能增加瑞舒伐他汀诱导的肌毒性风险,建议此类患者降低瑞舒伐他汀剂量。
研究设计与样本
- 前瞻性研究纳入159例受试者,另纳入已发表研究队列88例,进行单剂量瑞舒伐他汀药代动力学的全基因组关联分析和候选基因分析。
主要发现
- 全基因组关联荟萃分析显示SLCO1B1 c.521T>C与瑞舒伐他汀AUC升高相关(P=1.8×10-12),与峰浓度升高相关(P=3.2×10-15)。
- 候选基因分析提示ABCG2 c.421C>A与瑞舒伐他汀AUC升高相关(P=.0079)。
- SLCO1B1 c.388A>G与瑞舒伐他汀AUC降低相关(P=.0041),SLCO2B1 c.1457C>T与AUC降低相关(P=.0076)。
- OATP1B1功能减弱表型者瑞舒伐他汀AUC增加2.1倍(90%CI 1.6-2.8,P=4.69×10-5),OATP1B1功能高度增强表型者AUC降低44%(16-62%,P=.019)。
- ABCG2 c.421A/A基因型者瑞舒伐他汀AUC增加2.2倍(90%CI 1.5-3.0,P=2.6×10-4);SLCO2B1 c.1457C/T基因型者AUC降低28%(11-42%,P=.01)。
关键数值与推荐
- 基于SLCO1B1基因型将受试者分为OATP1B1功能减弱、正常、增强等组,功能减弱表型者瑞舒伐他汀AUC增加2.1倍。
- ABCG2 c.421A/A基因型者瑞舒伐他汀AUC增加2.2倍。
- SLCO2B1 c.1457C/T基因型者瑞舒伐他汀AUC降低28%。
- 建议SLCO1B1或ABCG2功能减弱基因型患者降低瑞舒伐他汀剂量。
临床怎么用
- 临床可考虑对使用瑞舒伐他汀的患者进行SLCO1B1和ABCG2基因分型,识别肌毒性高风险个体。
- 对携带SLCO1B1功能减弱或ABCG2 c.421A/A基因型的患者,建议降低瑞舒伐他汀剂量并监测肌毒性症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim was to comprehensively investigate the effects of genetic variability on the pharmacokinetics of rosuvastatin. METHODS: We conducted a genome-wide association study and candidate gene analyses of single dose rosuvastatin pharmacokinetics in a prospective study (n = 159) and a cohort of previously published studies (n = 88). RESULTS: In a genome-wide association meta-analysis of the prospective study and the cohort of previously published studies, the SLCO1B1 c.521 T > C (rs4149056) single nucleotide variation (SNV) associated with increased area under the plasma concentration-time curve (AUC) and peak plasma concentration of rosuvastatin (P = 1.8 × 10-12 and P = 3.2 × 10-15 ). The candidate gene analysis suggested that the ABCG2 c.421C > A (rs2231142) SNV associates with increased rosuvastatin AUC (P = .0079), while the SLCO1B1 c.388A > G (rs2306283) and SLCO2B1 c.1457C > T (rs2306168) SNVs associate with decreased rosuvastatin AUC (P = .0041 and P = .0076). Based on SLCO1B1 genotypes, we stratified the participants into poor, decreased, normal, increased and highly increased organic anion transporting polypeptide (OATP) 1B1 function groups. The OATP1B1 poor function phenotype associated with 2.1-fold (90% confidence interval 1.6-2.8, P = 4.69 × 10-5 ) increased AUC of rosuvastatin, whereas the OATP1B1 highly increased function phenotype associated with a 44% (16-62%; P = .019) decreased rosuvastatin AUC. The ABCG2 c.421A/A genotype associated with 2.2-fold (1.5-3.0; P = 2.6 × 10-4 ) increased AUC of rosuvastatin. The SLCO2B1 c.1457C/T genotype associated with 28% decreased rosuvastatin AUC (11-42%; P = .01). CONCLUSION: These data suggest roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics. Poor SLCO1B1 or ABCG2 function genotypes may increase the risk of rosuvastatin-induced myotoxicity. Reduced doses of rosuvastatin are advisable for patients with these genotypes.
引用
- Lehtisalo M, Taskinen S, Tarkiainen EK, et al. A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics. Br J Clin Pharmacol. 2022. PMID: 35942816. doi:10.1111/bcp.15485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。